Nuvitru wellness - peptide reference

Peptide therapy, explained with evidence and restraint.

A clinical library for the peptides patients ask about most: what they are, where the evidence is strongest, what is still uncertain, and what our team screens before any protocol decision.

Explore the library Safety screening

FDA Approved

FDA-approved as a prescription pharmaceutical. The strongest regulatory and clinical evidence in this guide.

Approved Abroad

Approved as a pharmaceutical in one or more non-U.S. markets. Substantial clinical use and regulatory review outside the U.S.

Prior FDA Approval

Previously FDA-approved; withdrawn for commercial — not safety — reasons. Adult anti-aging use is off-label compounding.

Phase 2 RCT

Positive Phase 2 randomized controlled trial data in a specific clinical indication. Phase 3 confirmation not yet completed.

Phase 3 — Mixed

Completed Phase 3 trial that did not meet its primary endpoint. Real human safety data exists; efficacy claims should be calibrated to trial outcomes.

Preclinical / Limited Human Data

Most evidence from animal models or cell culture. Human data is observational, very limited, or absent. Genuine research frontier.

Regulatory Warnings

Health authorities have issued explicit warnings citing serious adverse events. An FDA-approved alternative typically exists.

Browse by use case

Find the right clinical conversation.

These groupings are educational, not recommendations. Fit depends on history, labs, medications, contraindications, and the risk-benefit conversation with the care team.

01 Preclinical / Limited Human Data

BPC-157

Body Protection Compound-157

Tendon, ligament, muscle, and gut-lining repair.

Not FDA approvedView monograph

02 Phase 3 — Mixed

AOD-9604

Advanced Obesity Drug Fragment 9604

Fat loss, especially when growth-hormone–based options aren't a good fit.

Not FDA approvedView monograph

03 Phase 2 RCT

ARA-290

EPO-Derived Tissue-Protective Peptide

Nerve pain and nerve repair, especially in sarcoidosis-related neuropathy.

Not FDA approvedView monograph

04 Preclinical / Limited Human Data

DSIP

Delta Sleep-Inducing Peptide

Sleep quality and stress/cortisol balance.

Not FDA approvedView monograph

05 Preclinical / Limited Human Data

Epithalon

Epitalon — Tetrapeptide (Ala-Glu-Asp-Gly)

Longevity, sleep, and antioxidant support.

Not FDA approvedView monograph

06 Preclinical / Limited Human Data

GHK-Cu

Copper Peptide (Glycyl-L-Histidyl-L-Lysine Copper)

Skin anti-aging and wound healing — strongest as a topical (on-skin) product.

Strong topical evidenceView monograph

07 Phase 2 RCT

Kisspeptin

Kisspeptin-10 / Kisspeptin-54 (KISS1 Gene Product)

Fertility, restoring menstrual cycles, and certain hormone-axis problems.

Not FDA approvedView monograph

08 Regulatory Warnings

Melanotan II

Non-Selective Melanocortin Receptor Agonist

Generally not recommended — a safer, FDA-approved alternative (PT-141) exists for sexual function.

Explicit regulatory warnings (UK, AU, IE)View monograph

09 Preclinical / Limited Human Data

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

Metabolic health, insulin sensitivity, and exercise performance.

Not FDA approvedView monograph

10 FDA Approved

PT-141

Bremelanotide — FDA-APPROVED Melanocortin Agonist

Low sexual desire — approved for premenopausal women, used more broadly off-label.

Only FDA-approved peptide in this guideView monograph

11 Phase 3 — Mixed

SS-31

Elamipretide — Mitochondria-Targeting Tetrapeptide

Mitochondrial dysfunction, age-related energy decline, and certain heart conditions.

Not FDA approvedView monograph

12 Prior FDA Approval

Sermorelin

GHRH Analog — Growth Hormone Secretagogue

Body composition, sleep, recovery, and energy through growth-hormone support.

Prior FDA approval (Geref, withdrawn 2008 — commercial reasons, not safety)View monograph

13 FDA Approved

Tesamorelin

GHRH Analog — FDA-APPROVED for HIV-Associated Lipodystrophy

Reducing deep belly (visceral) fat and growth-hormone support.

FDA approved (Egrifta)View monograph

14 Approved Abroad

Thymosin α-1

Thymalfasin — Thymic Immunomodulatory Peptide

Immune support, chronic infections, and as a complement to cancer care.

Approved in multiple countries (Zadaxin)View monograph

15 Preclinical / Limited Human Data

TB-500

Thymosin Beta-4 Fragment (Ac-SDKP)

Muscle, tendon, and wound recovery.

Not FDA approvedView monograph

16 Preclinical / Limited Human Data

KPV

Alpha-MSH C-Terminal Tripeptide (Lys-Pro-Val)

Gut inflammation and inflammatory skin conditions.

Not FDA approvedView monograph

Before any protocol

Peptides start with screening, not shopping.

Nuvitru treats peptide therapy as a clinical decision. The page is intentionally designed to make limitations, regulatory status, and hard-stop topics as visible as potential benefits.

Active malignancy or cancer history Pregnancy or breastfeeding Under 18 Organ transplant or immunosuppression Cardiovascular disease or uncontrolled blood pressure Wilson's disease or copper metabolism concerns WADA-tested competitive athlete

Ready to talk through your options?

Book an introductory call to ask questions, discuss fit, and choose the right next step with the Nuvitru team.

Book an intro call